Recent Finacing
Recent Raise
Altor BioScience engineers targeted immunotherapies—soluble T‑cell antigen receptors, tissue‑factor–targeting monoclonal antibodies, and IL‑15 protein scaffolds—and advances clinical-stage candidates such as ALT‑801.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor